Adverse Drug Reaction Monitoring and Post-Marketing Re-Evaluation of Radioprotective Drugs
10.3870/j.issn.1004-0781.2025.10.020
- VernacularTitle:辐射防治药物不良反应监测及上市后再评价
- Author:
Peng ZHANG
1
;
Ran ZHANG
;
Minghui AN
;
Xinze WANG
;
Meilin WANG
;
Yuxuan ZHENG
;
Zhenjiang ZHANG
;
Dong CHAI
;
Jian GONG
Author Information
1. 沈阳药科大学药物流行病学与临床药物评价课题组,沈阳 110016
- Publication Type:Journal Article
- Keywords:
Radioprotective drugs;
Adverse drug reactions;
Post-marketing re-evaluation
- From:
Herald of Medicine
2025;44(10):1643-1647
- CountryChina
- Language:Chinese
-
Abstract:
With the widespread application of nuclear technology,the prevention and treatment of radiation damage have become significant issues in the fields of public health and medicine.This article reviews the adverse drug reactions and their monitoring for radioprotective drugs,and discusses their post-marketing re-evaluation in terms of safety,efficacy,economics,and quality standards.Research indicates that while there is a wide variety of radioprotective drugs,safety concerns are prevalent.Future efforts should focus on strengthening the monitoring and management of adverse drug reactions,optimizing drug safety,and exploring the potential of combined drug applications through multidisciplinary collaboration to enhance anti-radiation efficacy.
